CTLA4 and lung adenocarcinoma: Micro-CT image analysis revealed that mice treated with anti-PD-1/CTLA-4/Ly6C had a smaller percentage change of lung adenocarcinomas compared to mice treated with anti-PD-1/CTLA-4 by week 8 (Figure 3F).